282 related articles for article (PubMed ID: 17505000)
1. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.
Ekeblad S; Sundin A; Janson ET; Welin S; Granberg D; Kindmark H; Dunder K; Kozlovacki G; Orlefors H; Sigurd M; Oberg K; Eriksson B; Skogseid B
Clin Cancer Res; 2007 May; 13(10):2986-91. PubMed ID: 17505000
[TBL] [Abstract][Full Text] [Related]
2. Effect of temozolomide in patients with metastatic bronchial carcinoids.
Crona J; Fanola I; Lindholm DP; Antonodimitrakis P; Öberg K; Eriksson B; Granberg D
Neuroendocrinology; 2013; 98(2):151-5. PubMed ID: 23969949
[TBL] [Abstract][Full Text] [Related]
3. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
Kulke MH; Hornick JL; Frauenhoffer C; Hooshmand S; Ryan DP; Enzinger PC; Meyerhardt JA; Clark JW; Stuart K; Fuchs CS; Redston MS
Clin Cancer Res; 2009 Jan; 15(1):338-45. PubMed ID: 19118063
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
Kulke MH; Stuart K; Enzinger PC; Ryan DP; Clark JW; Muzikansky A; Vincitore M; Michelini A; Fuchs CS
J Clin Oncol; 2006 Jan; 24(3):401-6. PubMed ID: 16421420
[TBL] [Abstract][Full Text] [Related]
5. Temozolomide: a safe and effective treatment for malignant digestive endocrine tumors.
Maire F; Hammel P; Faivre S; Hentic O; Yapur L; Larroque B; Couvelard A; Zappa M; Raymond E; Lévy P; Ruszniewski P
Neuroendocrinology; 2009; 90(1):67-72. PubMed ID: 19521065
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Abbasi S; Kashashna A; Albaba H
Pancreas; 2014 Nov; 43(8):1303-5. PubMed ID: 25036906
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
Papaxoinis G; Kordatou Z; McCallum L; Nasralla M; Lamarca A; Backen A; Nonaka D; Mansoor W
Neuroendocrinology; 2020; 110(5):413-421. PubMed ID: 31437838
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.
Chan JA; Stuart K; Earle CC; Clark JW; Bhargava P; Miksad R; Blaszkowsky L; Enzinger PC; Meyerhardt JA; Zheng H; Fuchs CS; Kulke MH
J Clin Oncol; 2012 Aug; 30(24):2963-8. PubMed ID: 22778320
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms.
Al-Toubah T; Morse B; Strosberg J
Oncologist; 2020 Jan; 25(1):e48-e52. PubMed ID: 31455747
[TBL] [Abstract][Full Text] [Related]
10. Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial.
Ollivier S; Fonck M; Bécouarn Y; Brunet R
Am J Clin Oncol; 1998 Jun; 21(3):237-40. PubMed ID: 9626788
[TBL] [Abstract][Full Text] [Related]
11. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Kaltsas G; Korbonits M; Heintz E; Mukherjee JJ; Jenkins PJ; Chew SL; Reznek R; Monson JP; Besser GM; Foley R; Britton KE; Grossman AB
J Clin Endocrinol Metab; 2001 Feb; 86(2):895-902. PubMed ID: 11158063
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
Claringbold PG; Turner JH
Neuroendocrinology; 2016; 103(5):432-9. PubMed ID: 26065489
[TBL] [Abstract][Full Text] [Related]
13. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Crespo G; Jiménez-Fonseca P; Custodio A; López C; Carmona-Bayonas A; Alonso V; Navarro M; Aller J; Sevilla I; Grande E; Gajate P; Alonso-Gordoa T; Matos I; Capdevila J; Nieto B; Barriuso J
Future Oncol; 2017 Mar; 13(7):615-624. PubMed ID: 27802780
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas.
Olsen IH; Sørensen JB; Federspiel B; Kjaer A; Hansen CP; Knigge U; Langer SW
ScientificWorldJournal; 2012; 2012():170496. PubMed ID: 22973169
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience.
Hatton MQ; Reed NS
Clin Oncol (R Coll Radiol); 1997; 9(6):385-9. PubMed ID: 9448967
[TBL] [Abstract][Full Text] [Related]
17. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
[TBL] [Abstract][Full Text] [Related]
18. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors.
Mueller D; Krug S; Majumder M; Rinke A; Gress TM
BMC Cancer; 2016 Aug; 16():645. PubMed ID: 27538897
[TBL] [Abstract][Full Text] [Related]
19. Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines.
Larsson DE; Hassan S; Larsson R; Oberg K; Granberg D
Cancer Chemother Pharmacol; 2009 Dec; 65(1):5-12. PubMed ID: 19381631
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses.
de Mestier L; Walter T; Brixi H; Evrard C; Legoux JL; de Boissieu P; Hentic O; Cros J; Hammel P; Tougeron D; Lombard-Bohas C; Rebours V; Ruszniewski P; Cadiot G
Neuroendocrinology; 2019; 108(4):343-353. PubMed ID: 30759445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
